These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8305538)

  • 21. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of immunotherapy for the treatment of malignancies refractory to conventional therapies.
    Kim S; Haas GP; Hillman GG
    Cytokines Mol Ther; 1996 Mar; 2(1):13-9. PubMed ID: 9384685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT; Kradin RL
    Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
    [No Abstract]   [Full Text] [Related]  

  • 25. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
    Guo H; Qian X
    Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer.
    Gomez GG; Hutchison RB; Kruse CA
    Cancer Treat Rev; 2001 Dec; 27(6):375-402. PubMed ID: 11908930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Strategies for gene therapy of melanoma].
    Dummer R; Davis-Daneshfar A; Döhring C; Döbbeling U; Burg G
    Hautarzt; 1995 May; 46(5):305-8. PubMed ID: 7607892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.
    Rosenberg SA; Spiess P; Lafreniere R
    Science; 1986 Sep; 233(4770):1318-21. PubMed ID: 3489291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adoptive immunotherapy of experimental tumors using cytotoxic lymphocytes to carry and deliver toxins.
    Zanovello P; Rosato A; Bronte V; Cerundolo V; Collavo D
    Ann Ist Super Sanita; 1991; 27(1):91-5. PubMed ID: 1958033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Adoptive immunotherapy: evaluation and perspectives in the treatment of certain cancers].
    Bartholeyns J; Bardot V; Chokri M; Romet-Lemonne JL
    Rev Med Interne; 2000 Oct; 21(10):863-71. PubMed ID: 11075395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.
    Lutz-Nicoladoni C; Wallner S; Stoitzner P; Pircher M; Gruber T; Wolf AM; Gastl G; Penninger JM; Baier G; Wolf D
    Immunol Cell Biol; 2012 Jan; 90(1):130-4. PubMed ID: 21383769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular immunity and immunotherapy of brain tumors.
    Prins RM; Liau LM
    Front Biosci; 2004 Sep; 9():3124-36. PubMed ID: 15353342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular immunotherapy: a new avenue in internal medicine.
    Toungouz M; Velu T; Thielemans K
    Acta Clin Belg; 1998 Feb; 53(1):9-18. PubMed ID: 9562700
    [No Abstract]   [Full Text] [Related]  

  • 36. Adoptive T-cell immunotherapy of cancer.
    Li Q; Chang AE
    Cytokines Cell Mol Ther; 1999 Jun; 5(2):105-17. PubMed ID: 10515683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefits of a continuous therapy for cancer patients with a novel adoptive cell therapy by cascade priming (CAPRI).
    Wank R; Song X; Gu S; Laumbacher B
    Immunotherapy; 2014; 6(3):269-82. PubMed ID: 24762072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Augmentation of therapeutic effect of adoptive immunotherapy through a synergy between transferred killer cells and host's fresh lymphocytes].
    Kan N; Yamasaki S; Harada T; Satoh K; Ichinose Y; Moriguchi Y; Kodama H; Ohgaki K
    Hum Cell; 1992 Sep; 5(3):236-42. PubMed ID: 1467322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NK cell-based cancer immunotherapy: from basic biology to clinical application.
    Li Y; Yin J; Li T; Huang S; Yan H; Leavenworth J; Wang X
    Sci China Life Sci; 2015 Dec; 58(12):1233-45. PubMed ID: 26588912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.